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Abstract
Background: Stress and various stress hormones, including catecholamines and glucocorticoids, have recently been
implicated in the pathogenesis of Alzheimer’s disease (AD), which represents the greatest unresolved medical challenge in
neurology. Angiotensin receptor blockers have shown benefits in AD and prone-to-AD animals. However, the mechanisms
responsible for their efficacy remain unknown, and no studies have directly addressed the role of central angiotensin II (Ang
II), a fundamental stress hormone, in the pathogenesis of AD. The present study focused on the role of central Ang II in
amyloidogenesis, the critical process in AD neuropathology, and aimed to provide direct evidence for the role of this stress
hormone in the pathogenesis of AD.
Methodology/Principal Findings: Increased central Ang II levels during stress response were modeled by intracerebroven-
tricular (ICV) administration of graded doses of Ang II (6 ng/hr low dose, 60 ng/hr medium dose, and 600 ng/hr high dose,
all delivered at a rate of 0.25 ml/hr) to male Sprague Dawley rats (280–310 g) via osmotic pumps. After 1 week of continuous
Ang II infusion, the stimulation of Ang II type 1 receptors was accompanied by the modulation of amyloid precursor protein,
a-, b-and c-secretase, and increased b amyloid production. These effects could be completely abolished by concomitant ICV
infusion of losartan, indicating that central Ang II played a causative role in these alterations.
Conclusions/Significance: Central Ang II is essential to the stress response, and the results of this study suggest that
increased central Ang II levels play an important role in amyloidogenesis during stress, and that central Ang II-directed stress
prevention and treatment might represent a novel anti-AD strategy.
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Introduction
Alzheimer’s disease (AD) is the most common neurodegener-
ative disorder worldwide [1]. It is characterized neuropatholog-
ically by the formation of senile plaques and neurofibrillary
tangles, and clinically by the progressive deterioration of memory
and other cognitive functions [2], which cannot be prevented
using currently available treatments [3]. Senile plaques are
primarily composed of a 40–42-amino acid peptide denoted as b
amyloid (Ab), which is derived from sequential cleavage of
amyloid precursor peptide (APP) by b-secretase and c-secretase
(the amyloidogenesis pathway) [1].The accumulation and deposi-
tion of Ab in selective brain regions is a major cause of
neurotoxicity and is assumed to be a culprit for inducing the
pathologic processes of AD [4]. However, APP can also be
processed by an a–c secretase stepwise pathway, which precludes
the generation of Ab (the antiamyloidogenesis pathway).
Several years after the publication of descriptive reports of a-
secretase, three responsible enzymes, belonging to the A Disin-
tegrin And Metalloproteinase (ADAM) family, have been
identified with a-secretase activity: ADAM 9, ADAM 10, and
ADAM 17[5]. Moreover, a recent knockdown study confirmed
that ADAM 10, but surprisingly not ADAM 9 or ADAM 17, was
the physiologically relevant, constitutive a-secretase of APP [6].
The identity of b-secretase has also been studied, and a novel
aspartyl protease, named the b-site APP-cleaving enzyme
(BACE1), was revealed in five independent reports [7–11]. BACE1
cleavage of APP has subsequently been proven to be a prerequisite
for Ab generation [12]. c-secretase is a membrane-embedded
protease complex consisting of presenilin 1 (PS1), nicastrin,
anterior pharynx-defective 1, and presenilin enhancer 2 [13]. c-
secretase specificity determines the ratio of two peptide products,
Ab40 and the more neurotoxic Ab42, and mutations in its catalytic
subunit PS1, which lead to an increased Ab42/Ab40 ratio, account
for most cases of genetic AD [14]. However, because genetic AD
accounts for only a small percentage (probably less than 1%) of the
total number of cases [15], the development of sporadic AD is still
linked to environmental influences. Stress, particularly chronic
adverse stress, is one of the environmental factors that has been
suggested to contribute to the onset and progression of AD [16].
The stress response is often associated with high levels of stress
hormones, such as catecholamines (CAs, effectors of the
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effectors of the hypothalamic pituitary adrenal axis), and their
regulator, central angiotensin II (Ang II) [17]. Both CAs [18,19]
and GCs [20,21] are known to be linked to the pathogenesis of
AD, but their regulator, central Ang II, deserves further
consideration.
Central Ang II, by binding the Ang II type 1 receptor (AT1R) at
all key hypothalamic regulatory centers or higher centers, plays a
critical role in the activation of the sympathetic adrenomedullary
system and hypothalamic pituitary adrenal axis, as well as in the
secretion of CAs and GCs [17,22]. Central Ang II has thus been
accepted as a fundamental stress hormone in the body [17,23].
However, central Ang II has also been implicated in several central
nervous system disorders. For example, hippocampal Ang II-
immunopositive neurons with distorted processes were detected in
Ab deposits in AD brains [24], and enhanced immunoreactivity of
Ang II, AT1R, and angiotensin-converting enzyme (ACE) was
found in a postmortem examination of patients with AD [25].
Moreover, some studies also showed that Ang II could inhibit
potassium-mediated release of acetylcholine [26,27], induce
oxidative stress[28], activation of mitogen-activated protein kinases
(MAPKs) [29], and inflammation [30], and was involved in blood–
brain barrier maintenance [31] and cell survival [32], all of which
are relevant to AD [32–35]. When administered to AD and prone-
to-AD animals, some Ang II receptor blockers (ARBs), such as
losartan, valsartan, candesartan, telmisartan, and olmesartan, were
associated with improved cognitive impairment and/or attenuated
Ab production [36–40]. It is therefore vitally important to
determine the potential role of Ang II in AD, especially in
amyloidogenesis, given the proven involvement of stress and stress
hormones in the pathogenesis of AD. The present study therefore
usedaratmodelofADtoprovidedirectevidencefortheroleofAng
II in amyloidogenesis and the pathogenesis of the disease.
Results
Central Ang II Stimulation Caused a Dose-dependent
Increase in AT1R expression
AT1R mRNA and protein levels were assayed using quantita-
tive polymerase chain reaction (qPCR) and western blotting (WB),
respectively, after intracerebroventricular (ICV) administration of
Ang II. A dose-dependent increase in AT1R mRNA levels was
observed 1 week after central infusion of graded doses of Ang II.
An almost 1.5-fold increase was observed following medium-dose
Ang II stimulation, which was attenuated by combination with
losartan. Losartan infusion alone had no effect on AT1R mRNA
(p.0.05) (Figure 1A). Similar changes in AT1R protein levels
were identified by WB (Figure 2A and 2B).
These results suggest that central AT1R expression could be
dose-dependently elevated by increased central Ang II, as
confirmed by concomitant losartan administration, and that
baseline AT1R expression was unaffected by ARBs, in the absence
of stimulation by specific ligands.
Central Ang II Stimulation Downregulated Full-length
APP Protein but Upregulated its mRNA
Full-length APP protein levels were analyzed using a carboxyl-
terminal-directed antibody that recognizes the carboxyl terminal
fragments (CTFs) and the full-length APP holoproteins (mature
APP or mAPP and immature APP or imAPP). The binding
capacity of the antibody has been confirmed in previous studies
[41–43]. WB showed a remarkable reduction in both mature and
immature APP holoprotein levels in central Ang II-treated
animals: about a 50% reduction with low-dose and medium-dose
Ang II (p,0.01), and about a 70% reduction with high-dose Ang
II (p,0.01), relative to saline-treated controls (Figure 2A and
Figure 2C). APP transcription analyzed by qPCR showed an
almost 2-fold increase in all Ang II-treated animals (p,0.01)
(Figure 1B). These effects were abolished by concomitant
losartan treatment, and could therefore be attributed to Ang II.
Central Ang II Stimulation Had Different Effects on
Secretase Expression
mRNA and protein levels of ADAM 10, BACE 1, and PS1,
representing the expression levels of a-, b-, and c-secretase, were
also evaluated. As shown in Figure 1C, Figure 2A and
Figure 2D, ADAM 10 mRNA and protein remained at baseline
levels after infusion of central Ang II or its blockers for 1
week(p.0.05), implying that central Ang II stimulation failed to
affect ADAM 10 expression.
However, BACE1 mRNA, assessed by qPCR, was increased
1.3-fold following low-dose (p,0.01), and 1.6-fold following
medium-dose Ang II treatment (p,0.01), and almost 2.1-fold
following high-dose Ang II treatment (p,0.01) (Figure 1C).
BACE1 protein levels assessed by WB also showed dose-dependent
increases in the Ang II-treated groups (Figure 2A and 2D). The
marked increases in BACE1 mRNA and protein levels following
medium-dose Ang II treatment were normalized by losar-
tan(p.0.05), implying that these alterations were associated with
central Ang II stimulation.
Regarding PS1 levels, low-dose Ang II infusion had no effect on
PS1 gene expression (p.0.05), whereas medium-dose and high-
dose Ang II infusions were followed by a significant increase
(p,0.01), and an even higher increase (p,0.01), respectively.
These increases were cancelled by blockade of AT1R with losartan
(Figure 1C), suggesting that they were induced by stimulation of
AT1R. PS1 protein expression analyzed by WB showed similar
changes to those demonstrated for its gene expression.
Central Ang II Stimulation Had Different Effects on
Secretase Activity
The activities of a, b-, and c-secretase were evaluated by
measuring the fluorescence intensity after incubation with a
synthetic fluorescent peptide substrate.
As shown in Figure 3, no significant alterations in a-secretase
activity were shown in any Ang II-treated animals(p.0.05),
suggesting that central Ang II had no effect on the activity of a-
secretase.
b-secretaseactivitywasincreased less than1.4-foldfollowingboth
low-dose and medium-dose Ang II(p,0.05), but by almost 2.5-fold
by high-dose Ang II(p,0.01) (Figure 3). Then, enhanced b-
secretase activity was blocked by losartan and disappeared in single
losartan, suggesting that the enhanced activity was due to Ang II.
The results of activity assay for c-secretase are shown in
Figure 3. Treatment with graded doses of Ang II was followed by
an approximately 1.6–1.8–2.9-fold stepwise increase in c-secretase
activity, with no significant difference in activities between low-
dose and medium-dose Ang II treatment (p.0.05). The increase
following medium-dose Ang II treatment was normalized by
concomitant losartan treatment (p.0.05), supporting the causative
role of Ang II in these changes.
Central Ang II Stimulation Caused Significant Alterations
in the Levels of APP a-CTF (C83) and b-CTF (C99),
Concentrations of Ab40 and Ab42, and Ab42/Ab40 Ratios
Cleavage of APP by a-o rb-secretase results in the production
of APP CTFs, i.e., C83 and C99, the latter of which is the direct
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mentioned above, the antibody that recognizes full-length APP
can also be used to detect its CTFs, C83 and C99.
When normalized to b-actin, WB of C83 showed an almost 1.3-
fold increase following medium-dose Ang II treatment (p,0.05),
but no changes in response to other doses of Ang II (p.0.05)
(Figure 2A and 2E). Simultaneous WB of C99 showed an
approximately 2.0-fold increase following low-dose and medium-
dose Ang II treatments (p,0.01), but a 1.8-fold increase following
high-dose Ang II treatment (p,0.01) (Figure 2A and 2E). The
productions of C83 and C99 were represented after normalization
to both b-actin and APP. As shown in Figure 2F, when
normalized to b-actin and then immature APP (imAPP), C83
production showed a 2.3-fold increase following low-dose and
medium-dose Ang II (p,0.01), and a higher 3.3-fold increase
following high-dose Ang II treatment (p,0.01). C99 production
Figure 1. Expression assays for AT1R and APP processing pattern by qPCR. Expression analysis showing the normalized mRNA levels of (A)
AT1R, (B) APP, (C) ADAM 10, BACE1 and PS1. n=7 for AT1R and n=6 for all others. CTs (threshold cycles) were used as the readout. The results were
obtained using the comparative Ct method and the arithmetic formula 2
2DDCt
. Data were normalized to b-actin and represented as fold increases
over saline controls. *p,0.05 or **p,0.01 versus the control group receiving saline infusion.
doi:10.1371/journal.pone.0016037.g001
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response to low-dose Ang II (p,0.01), a 3.5-fold increase following
medium-dose Ang II (p,0.01), and a 5.3-fold increase following
high-dose Ang II (p,0.01).
The concentration of Ab in the rat cerebral cortices was
analyzed by sandwich ELISA. As shown in Figure 4A and
Figure S1, low-dose Ang II treatment produced a 1.3-fold
increase in Ab40 concentration (from 30.2660.56 in controls to
40.3860.70, p,0.01), but a 1.5-fold increase in Ab42 concentra-
tion (from 4.2360.17 in controls to 6.2060.14, p,0.01). When
the dose of Ang II was increased by 10-fold, the increase in Ab40
increased by almost 2-fold (to 59.9860.84, p,0.01), but no
further significant increase in Ab42 concentration occurred
(6.3160.16). A further 10-fold increase in Ang II resulted in
increases in Ab40 and Ab42 concentrations of nearly 2.5-fold
(to 75.4861.89, p,0.01) and 3-fold (to 13.2060.32, p,0.01),
respectively. These effects did not occur following the administra-
tion of concomitant or single losartan (p.0.05).
We also calculated the Ab42/Ab40 ratios in the same samples.
As shown in Figure 4B, the ratio was approximately
0.14060.007 in the controls animals, and this increased to
0.15460.005 following low-dose Ang II treatment (p,0.01), but
decreased to 0.10560.003 following medium-dose Ang II
treatment (p,0.01). After a rebound increase to 0.17560.008
following treatment with high-dose Ang II (p,0.01), the ratios
Figure 2. Expression assays for AT1R and APP processing pattern by WB. The same gels were blotted for b-actin as an internal standard.
n=6 for each group. (A) Representative enhanced chemiluminescence radiographs of immunoblots showing the immunoactivities of AT1R, APP,
ADAM 10, BACE1, PS1, C83, C99 and b-actin. Density analysis showing levels of (B)A T 1R, (C) APP, (D) ADAM 10, BACE1, and PS1, (E)( F) C83 and C99.
Data in (B–E) were normalized by dividing the density of the AT1R, ADAM 10, BACE1, PS1, C83 and C99 bands by the density of the b-actin band. Data
in (F) were normalized by dividing the density of the C83 and C99 band by that of the b-actin band and then the imAPP band. All data were
represented as fold increases over the saline controls. *p,0.05 or **p,0.01 versus the control group receiving saline infusion. imAPP, immature APP;
mAPP, mature APP; imADAM 10, immature ADAM 10;mADAM 10, mature ADAM 10.
doi:10.1371/journal.pone.0016037.g002
Figure 3. Activity assays for a-, b- and c-secretase. Activity
analysis showing activity levels of a-, b-and c-secretase. Data are
represented as fold increases over saline controls. n=5 for each group.
All samples were analyzed in duplicate. *p,0.05 or **p,0.01 versus the
control group receiving saline infusion.
doi:10.1371/journal.pone.0016037.g003
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single losartan treatment (p.0.05).
The effects of medium-dose Ang II on C83 and C99 levels,
concentrations of Ab40 and Ab42, and on the Ab42/Ab40 ratios
were attenuated or even abolished by blocking AT1R signaling,
confirming that these effects resulted from central Ang II binding
to AT1R.
Discussion
Ang II has multiple tasks in the brain and plays key roles in the
regulation of blood pressure, fluid homeostasis, cerebral blood
flow, and the response to stress [45]. These classical, well-defined
actions of Ang II in the brain are mediated by stimulation of the
AT1R [45]. Stress enhances the production of peripheral and
brain Ang II [46–48] and the expression of peripheral and brain
AT1R [46,49–51]. Ang II does not readily cross the blood–brain
barrier, and the present study therefore used ICV Ang II
administration in rats to model the increased central Ang II levels
occurring during the stress response. Both gene and protein levels
of AT1R were dose-dependently upregulated after 1 week of ICV
Ang II infusion, suggesting that self-upregulation of AT1R
expression occurred after stimulation by Ang II, in accordance
with the results of previous studies [52–55]. The regulation of
AT1R expression and stimulation is important, as it determines the
level of activation of the brain Ang II system [22].
APP is the source of Ab. In the present study, graded doses of
central Ang II caused a 50–70% reduction in the level of APP
protein, which did not correspond to the more significant increases
in the production of C83, C99, and Ab. This discrepancy implies
that APP expression and processing were enhanced by central Ang
II, which was further supported by the upregulation of APP
mRNA levels.
APP is predominately cleaved by a-secretase under physiologic
conditions [56]. In the current study, central Ang II had no effect
on ADAM 10 protein or mRNA levels or activity. However,
although a-secretase expression was represented by the level of
ADAM 10 in this study, other members of the ADAM family,
including ADAM 9 and ADAM 17, have also been proposed to
display a-secretase activities [5]. Even a close homolog of BACE1,
BACE2, has been found to be responsible for a-secretase-like
proteolytic cleavage of APP [57,58]. Thus the regulation of other
putative a-secretase enzymes by Ang II should also be assayed.
BACE1 is the initiating and putatively rate-limiting enzyme in
Ab generation [59]. Levels of BACE1 mRNA and protein were
elevated by Ang II in the current study. Previous studies found that
the BACE1 promoter contains a number of putative transcription
factor-binding sites, including nuclear factor kappa-light-chain-
enhancer of activated B cells (NFkB) [60], activator protein 1
(AP 1) [61] and cAMP response element-binding protein (CREB)
[61]. Activation of these transcription factors is involved in Ang II
signaling [52,55,62], and this mechanism may therefore provide a
basis for Ang II-induced BACE1 expression. Significant increases
in b-secretase activity were also observed in this study. Oxidative
stress has recently been identified as a factor involved in the
stimulation of b-secretase activity [63,64], and is also well
implicated in Ang II signaling [28]. The stimulation of b-secretase
might thus result from Ang II-mediated oxidative stress. Several
reports have reported BACE1 to be a stress-response protein, or b-
secretase to be a stress-induced protease, because BACE1
expression and activity were elevated following acute or chronic
stress [59]. This might suggest a potential link between stress-
induced Ang II and altered BACE1 expression and activity.
The lack of a-secretase stimulation was expected to be reflected
in a lack of C83 production, while significant increases in BACE1
expression and activity were expected to be associated with
proportionate changes in C99 production. However, when
normalized to b-actin, an almost 1.3-fold increase in C83 levels
was detected following medium-dose Ang II administration,
though low-dose and high-dose Ang II had no effects, and high-
Figure 4. Production assays for Ab40 and Ab42 by ELISA. (A) Concentrations of Ab40 and Ab42 in rat cortices. Data are represented as fold
increases over saline controls. n=6 for each group. All samples were analyzed in duplicate. (B)A b42/Ab40 ratios. Data were calculated by dividing the
Ab42 concentration by the Ab40 in the same sample. *p,0.05 or **p,0.01 versus the control group receiving saline infusion.
doi:10.1371/journal.pone.0016037.g004
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while low-dose and medium-dose Ang II produced 2-fold
increases. This inconsistency between C99 levels and significant
alterations in BACE1 suggests that C99 was short-lived. On the
other hand, the uncoupling of a-secretase activity and C83 levels
might imply the existence of an additional mechanism for the
production of C83. Recent studies have reported that C99 could
be converted to C83 by a-secretase [6,65], which could account
for the C83 levels observed in the current study. This possibility is
further supported by the sharp increases in C83 levels and the
opposite effects of medium-dose Ang II on C83 and C99, after
normalization to both b-actin and APP.
PS1 is a key determinant of c-secretase activity [66]. We
analyzed the expression of PS1 and found that stimulation of the
AT1R by medium-dose or high-dose Ang II was accompanied by
increased PS1 expression, though these changes were not observed
after low-dose Ang II infusion. As a c-secretase catalytic subunit,
increased PS1 expression has often been found to occur
simultaneously with augmented c-secretase activity [67], while
repression of PS1 transcription inhibited c-secretase mediated
processing of APP [68]. However, overexpression of PS1 was not
sufficient to generate increased c-secretase activity or produce
more products in previous studies[69], suggesting that PS1 does
not act alone. Given the complicated situation, c-secretase
enzymatic activity in this study was evaluated in homogenates in
toto, and equivalent enhancements were observed following low-
dose and medium-dose Ang II treatment, with greater enhance-
ment after high-dose treatment. Although the current study was
unable to elucidate the precise mechanism of AT1R regulation of
c-secretase, several lines of evidence have indicated possible
mechanisms, as follows: central Ang II is well known to induce the
activation of some transcription factors, such as AP 1 [52], NFkB
[55] and CREB [62], which have been localized in PS1 promoter
and implicated in PS1 gene expression [67,70–72]. Ang II could
also induce the activation of several MAPK members, which have
been associated with enhanced c-secretase activity [73]. These
results imply that activation of AT1R could promote PS1
expression through the activation of transcription factors, and
could mediate the direct phosphorylation of PS1 or c-secretase at
specific sites by targeting the MAPK pathway. Second, recent
studies have shown that CAs can enhance c-secretase activity by
inducing autophagy [18], and because central Ang II promotes
CA utilization [74], this may represent an indirect pathway
whereby central Ang II can regulate c-secretase activity. However,
the study indicating that CAs promote amyloidogenesis by
inducing autophagy was performed in vitro[18], and further
research is needed to confirm these results in vivo.
Changes in the processing pathway of APP resulted in increased
Ab production; a dose-dependent increase in secreted Ab40
concentration, and a 1.5–3-fold increase in Ab42 concentration
were achieved following Ang II stimulation. Notably, the Ab42/
Ab40 ratios were altered. This ratio was linked to specificity of c-
secretase in previous studies [75,76], implying that Ang II could
cause shifts in APP amyloidogenic processing. Furthermore, the
neurotoxicity of Ab was recently shown to be associated with small
changes in the Ab42/Ab40 ratio [77], and Ang II-induced shifts in
this ratio should thus be taken into serious consideration.
However, losartan given together with medium-dose Ang II
abolished all effects of Ang II on APP, the three secretases, and
Ab. These findings suggest that the actions of central Ang II in
amyloidogenesis are mediated by activation of the AT1R.
Hypertension has been identified as a strong risk factor for AD
in epidemiological studies [78,79]. ICV infusion of Ang II in the
present study might have resulted in an increase in blood pressure
(BP) in the rats. Furthermore, previous studies in both animals and
humans found that ARBs helped to preserve cognitive function
through a mechanism independent of their antihypertensive effects
[80–83]. The effects of systemic BP were outside the scope of the
current study. However, AD has recently been proposed to be a
vascular disease, rather than a neurodegenerative disease [84,85].
Because Ang II is a potent vasoactive peptide, stress-induced and
Ang II-involved hypertension may contribute to amyloidogenesis.
Thus further studies are needed to investigate the link between
hypertension, especially nonpharmacologic hypertension, and
amyloidogenesis.
In conclusion, the results of this study demonstrated that central
Ang II potentiated amyloidogenesis in vivo, through modulation of
various components of the APP processing pathway; these actions
could be completely abolished by concomitant ICV infusion of
losartan. This study not only provides direct etiological evidence
for central Ang II, a fundamental stress hormone, in the
pathogenesis of AD, but also suggests that ARBs, already used
in clinical settings, may be potentially effective agents for the
prevention and treatment of AD.
Materials and Methods
Reagents and preparation
Ang II (Sigma) was dissolved in sterile saline to 24 ng/ml,
240 ng/ml, and 2,400 ng/ml, as adapted from a recent study [86].
Losartan (Sigma) was added to 240 ng/ml Ang II to a
concentration of 800 ng/ml, which was adequate to abolish the
effects of 240 ng/ml Ang II in vivo, as verified in our preliminary
experiments.
Osmotic pumps (Alzet, model 2004) with a brain infusion kit
(Alzet) were filled with reagents or sterile saline and placed into
sterile saline at 37uC for at least 40 hours, according to the
manufacturer’s instructions. The pumps were designed to work at
a rate of 0.25 ml/hr. The actual doses of Ang II delivered into rat
brains were thus 6 ng/hr, 60 ng/hr and 600 ng/hr.
Animals and surgery
Male Sprague Dawley rats (from the National Rodent
Laboratory Animal Resources Shanghai branch of China)
weighing 280–310 g were housed in a controlled environment at
2562uC with alternating 12 hr light and dark cycles. They were
provided with food and water ad libitum. All rats were acclimatized
in our animal facility for at least 1 week before the experiments
were conducted. Animal care and experiment protocols were in
accordance with the Guide for the Care and Use of Laboratory
Animals of Nanjing Medical University and were approved by the
Biological Research Ethics Committee of Nanjing Medical
University (permit number: NYLL2009-0005). All surgery was
performed under anesthesia and all efforts were made to minimize
the suffering of the animals.
A total of 54 rats were randomly divided into six groups,
according to the materials in the pumps: sterile saline; low-dose
Ang II; medium-dose Ang II; high-dose Ang II; medium-dose Ang
II + losartan; and losartan. Animals in each group were subjected
to ICV administration via a pump for 7 days. Pump implantation
was carried out using a well-established procedure in our
department [87]. In brief, animals were anaesthetized by
intraperitoneal injection of 10% chloral hydrate (0.35 ml/100 g).
Anaesthetized rats were placed in a stereotactic frame (David
Kopf), and the skull was exposed under sterile surgical conditions.
Stainless steel cannulas from the brain infusion kit were implanted
in the right lateral ventricle, relation to the bregma, at: 1.4 mm
lateral and 0.8 mm posterior on the right. A right-sided burr-hole
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pumps were then installed in subcutaneous pockets on the lateral
dorsum of the rats. Dental cement was used to affix the catheters
to the skull, and the wounds were closed with sutures. Body
temperature was monitored throughout the procedure using a
rectal temperature probe and maintained at 3760.5uC with a
thermostatically-controlled infrared lamp.
After 7 days, anaesthetized animals were sacrificed by decapita-
tion and brains were immediately dissected on ice, frozen in liquid
nitrogen, and maintained at 280uC until assayed.
Total RNA extraction, reverse transcription (RT) and qPCR
assay of gene expression
Cortices were homogenized in 10 volumes of TRIzol reagent
(Invitrogen) and total RNA was extracted, according to the
manufacturer’s instructions. The quantity and quality of the
resulting RNA were validated using a spectrophotometer (Hita-
chi). Of the total RNA, 500 ng was reverse transcribed to cDNA
using a RT reagent kit (Takara) at 37uC for 15 minutes, followed
by 85uC for 5 seconds, according to the manufacturer’s
instructions. The products were then stored at 220uC until use.
For quantitative SYBR Green (26SYBR premix Ex Taq, Takara)
real-time PCR, equal amounts of cDNA were used for each
reaction. Primer sequences were designed using primer 3 software
as follows:
murine b-actin: 59-AGCTATGAGCTGCCTGACGGC-39
and 59-CATGGATGCCACAGGATTCCA-39;
murine AT1R: 59-CCTCTACGCCAGTGTGTTCC-39 and
59-GCCAAGCCAGCCATCAGC-39;
murine APP: 59-GTGAGCGACGCCCTTCTCGTGCC-39
and 59-TCCGTGTCAAAGTTGTTCCTGTTGC-39;
murine ADAM 10: 59-GCCTATGTCTTCACGGACCG-39
and 59-TGCCAGACCAAGAACACCAT-39;
murine BACE 1:59-CATTGCCATCACTGAAT-39 and 59-
CAGTGCCTCAGTCTGGTTGA-39;
murine PS1: 59-GAGGAAGACGAAGAGCTGACAT-39and
59-GAAGCTGACTGACTTGATGGTG-39.
A two-step qPCR was performed using an ABI 7500 Real-Time
PCR System (Applied Biosystems). After 30 seconds of initial
denaturation at 95uC, the thermal profile included 40 two-step
cycles: step 1 for denaturation at 95uC for 5 seconds and step 2 for
annealing and extension at 60uC for 34 seconds. Data were
collected at step 2. The results were obtained using the
comparative Ct method and the arithmetic formula 2
2DDCt.
Tissue extraction for protein- and peptide-directed assays
To extract total protein, cortices were placed in 10 volumes of
ice cold RIPA buffer (50 mmol/l Tris-HCL, 150 mmol/l sodium
chloride, 1% Triton X-100, 1% sodium deoxycholate, 0.1%
sodium dodecyl sulfate) supplemented with protease inhibitors
(Sigma). The tissue was homogenized for 10 s in an ultrasound
homogenizer (IKA Laboratory). Tissue homogenates were then
centrifuged for 15 min at 12,500 g at 4uC (Beckman). Superna-
tants were carefully collected.
For Ab concentration assays, tissue extracts were prepared as
described previously [88], with some modifications. Cortical
tissues were homogenized in 10 volumes of high-salt buffer
(100 mmol/l Tris-HCL, pH 7.0, 1 mmol/l EGTA, 0.5 mmol/l
magnesium sulfate, 750 mmol/l sodium chloride, 20 mmol/l
sodium fluoride) containing protease inhibitors (Sigma). Soluble
Ab was extracted using diethyl acetate 0.4% in 100 mmol/L
sodium chloride and the sample was centrifuged for 60 min at
100,000 g at 4uC (Beckman). The supernatants were carefully
collected and then neutralized by adding 500 mmol/l Tris-HCL,
pH 6.8.
Protein quantification was performed using the supernatants,
according to the Bradford method. All the resulting supernatants
were frozen at -80uC until analysis.
Antibodies and western blotting (WB)
The following primary antibodies and working dilutions were
used: rabbit polyclonal anti-APP carboxyl terminal (Sigma,
1:5,000), rabbit polyclonal anti-ADAM 10 (Millipore, 1:500), rabbit
monoclonalanti-BACE1 (Cell Signaling, 1:500),mouse monoclonal
anti-PS1 that recognizes the PS1 amino terminal (Abcam, 1:250),
mouse monoclonal anti-AT1R, which recognizes the AT1R
carboxyl terminal (Abcam, 1:125), and mouse monoclonal anti-b
actin (Sigma, 1:1,000). Equal amounts of protein extracts (about
60 mg) were electrophoresed in sodium dodecyl sulfate-polyacryl-
amide gels (Bio-Rad). Proteins were transferred onto polyvinylidene
difluoridemembranes (Millipore). Non-specificbindingwas blocked
with 5% non-fat dried milk in 50 mmol/l Tris-HCL, pH 7.4,
containing 200 mmol/l sodium chloride and 0.5 mmol/L Tween
20 (Tris-buffered saline Tween). The blots were incubated with
different primary antibodies, followed by incubation with peroxi-
dase-conjugated anti-mouse or anti-rabbit immunoglobulins in
Tris-buffered saline Tween containing 10% non-fat dried milk.
Reactions were developed with an enhanced chemiluminescence
system, according to the manufacturer’s protocols (Pierce). The
blots were then exposed to films (Kodak) for various periods of time
(0.05–5 min). Data were normalized to the b-actin band.
Fluorogenic substrate assay
Assays to evaluate secretase activity were performed according
to a recent study [89]. Briefly, rat cerebral cortices were isolated
and homogenized. The resulting aliquots (containing 15 mgo f
proteins) were centrifuged at 12,000 g for 10 min (Beckman). The
membrane-enriched fractions were then incubated at 37uC for
30 min in 50 ml assay reaction buffer (for a-secretase, 10 mmol/L
Tris-HCL, pH 6.8; for b-secretase, 50 mmol/l sodium acetate,
pH 4.5; for c-secretase, 50 mmol/l Tris-HCL, pH 6.8, 2 mmol/l
EDTA, 0.25% CHAPSO) containing 10 mmol/l fluorescent
conjugated peptide substrate (Calbiochem) at 37uC for 2 hr. The
degree of substrate cleavage was measured as the emitted
fluorescence using a reader (Tecan) at excitation/emission
wavelengths of 325/393 nm (for a-secretase), 320/420 nm (for
b-secretase) and 355/440 nm (for c-secretase).
Enzyme-linked immunosorbent assay (ELISA)
The levels of soluble Ab40 and Ab42 in rat cerebral cortices were
detected using sandwich ELISA kits (Wako), according to the
manufacturer’s instructions. All samples were analyzed in
duplicate.
Statistical analysis
Data were analyzed using analysis of variance (ANOVA),
followed by least significant difference post hoc tests, using SPSS
13.0 software (SPSS). All results were expressed as mean6
standard deviation (SD).
Supporting Information
Figure S1 Concentration assays for Ab40 and Ab42 by
ELISA. n=6 for each group. All samples were analyzed in
duplicate. *p,0.05 or **p,0.01 versus the control group receiving
saline infusion.
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